Superseed: Will migrate from its own L2 to the Ethereum mainnet, users must bridge their assets before August 15
Foresight News reports that CDP lending protocol Superseed has announced it will abandon its own L2 network and migrate its entire ecosystem to the Ethereum mainnet to directly access Ethereum's liquidity and RWA ecosystem. Superseed stated that after abandoning its independent chain infrastructure, all engineering resources will be focused on application development. The core products will include the native lending protocol, the self-repaying stablecoin suprUSD, and the yield strategy Super Strategies, with protocol revenue used to replace L2 gas fees for repaying user loans. The Superseed L2 chain will be officially deactivated on August 15. Users holding assets such as USDC, USDT, cbBTC, ETH, etc., must complete cross-chain transfers before this date; the project cannot guarantee asset retrieval after the deadline. Users holding SUPR tokens who miss the deadline will have their balances recorded at deactivation and can later claim Ethereum native SUPR via a dedicated contract, with further details to be announced separately.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
